Abstract: A consumable management system comprising a consumable storage cluster with a plurality of storage compartments is presented. Each storage compartment is configured to receive one or more consumables. The consumable management system further comprises storage compartment indicators to provide guidance to a user and a detection unit for validating user action(s).

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: The present disclosure provides air-tight mechanical valves. In a general embodiment, the valves include a shaft and a segmented sleeve. The shaft includes a plurality of shaft ports distributed around a circumference of the shaft. The sleeve is configured to fit concentrically around the shaft and includes a body having at least two body pieces, at least one internal seal, and at least one set of a plurality of sleeve ports distributed around a circumference of the body. The plurality of sleeve ports cooperates with the plurality of shaft ports to facilitate fluid flow. The valves of the present disclosure advantageously reduce losses of pressure and compressed air during use.

Abstract: The present disclosure provides air-tight mechanical valves. In a general embodiment, the valves include a shaft and a segmented sleeve. The shaft includes a plurality of shaft ports distributed around a circumference of the shaft. The sleeve is configured to fit concentrically around the shaft and includes a body having at least two body pieces, at least one internal seal, and at least one set of a plurality of sleeve ports distributed around a circumference of the body. The plurality of sleeve ports cooperates with the plurality of shaft ports to facilitate fluid flow. The valves of the present disclosure advantageously reduce losses of pressure and compressed air during use.

Abstract: Air cartridge devices and methods of using the air cartridge devices are provided. In an embodiment, the present disclosure provides an air cartridge device comprising an elongated cylindrical shaft defining a first elongated end portion and a second elongated end portion. The second elongated end portion can defining one or more apertures. The air cartridge device can be incorporated into a blow molding apparatus for blow molding bottles.

Abstract: Air cartridge devices and methods of using the air cartridge devices are provided. In an embodiment, the present disclosure provides an air cartridge device comprising an elongated cylindrical shaft defining a first elongated end portion and a second elongated end portion. The second elongated end portion can defining one or more apertures. The air cartridge device can be incorporated into a blow molding apparatus for blow molding bottles.

Abstract: Air cartridge devices and methods of using the air cartridge devices are provided. In an embodiment, the present disclosure provides an air cartridge device comprising an elongated cylindrical shaft defining a first elongated end portion and a second elongated end portion. The second elongated end portion can defining one or more apertures. The air cartridge device can be incorporated into a blow molding apparatus for blow molding bottles.

Abstract: Air cartridge devices and methods of using the air cartridge devices are provided. In an embodiment, the present disclosure provides an air cartridge device comprising an elongated cylindrical shaft defining a first elongated end portion and a second elongated end portion. The second elongated end portion can defining one or more apertures. The air cartridge device can be incorporated into a blow molding apparatus for blow molding bottles.

Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.

Abstract: A portable, modular water garden structure, suitable for the containment of water and adapted to be readily assembled and disassembled, is provided. The structure first comprises a base unit, formed of a lightweight sturdy material, having an exposed outer surface, a top side, perimeter walls and an underside. The base unit is further characterized as having on its top side a generally centrally located depressed area suitable for use as a tub capable of accommodating an appropriate quantity of water. A moisture-proof flexible membrane is situated directly over the exposed outer surface area of the base unit, and extending over the tub and at least a portion of the upper edge of the perimeter walls. A layer of moisture- and flex-resistant material is formed over the moisture-proof membrane, covering the membrane and at least covering the exposed outside surfaces of the perimeter walls and any exposed outer surfaces of the base, so as to give a generally natural-looking appearance to said modular structure.

Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.

Abstract: A bioadhesive wound-healing composition includes pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids. The composition can be provided in the form of a film that does not self-adhere. The composition can include additional medicinal agents, such as polymyxin B sulfate, bacitracin zinc, and neomycin sulfate. Methods for producing the composition and methods for treating wounds with the composition are also disclosed.

Abstract: A denture adhesive which is useful in aiding in the retention of dentures to the oral mucosa constitutes a mixture of polyacrylic acid and hydroxy compound of sufficiently high molecular weight to be solid at room temperature. The combination can be used in the form of a powder or can be mixed in an oil base for application as a cream or liquid. The composition can also include hydration enhancers and pH adjustment agents.